Traditional small molecule kinase inhibitor drugs face numerous challenges, such as the propensity for drug resistance and the problem that some targets are undruggable. The proteolysis targeting chimera(PROTAC) technology utilizes the inherent ubiquitin-proteasome system in cells to achieve the degradation of proteins of interest(POI) for treating diseases, which can avoid the limitations of undruggable targets and drug resistance. Therefore, the PROTAC technology is expected to overcome the limitations of small molecule inhibitors. At present, some PROTACs have entered the clinical trial stage and are expected to become potential treatment methods for many diseases. This review introduces the biological mechanism, technical advantages, molecular design and clinical application prospects of PROTAC, hoping to provide a reference for its drug development and clinical application.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |